Legend Biotech sets ball rolling on $369m US IPO

Jonathan Breen

June 01, 2020 08:00 am

Biopharmaceutical company Legend Biotech Corp has kicked off bookbuilding for its Nasdaq IPO of up to $368.5m, according to a source familiar with the matter.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity IPOs Health and Biotech Equity Americas Jefferies LLC Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific United States Emerging Markets North America SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia